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Summary We undertook a trial of artesunate + amodiaquine (AS + AQ) and artesunate + sulphadoxine–
pyrimethamine (AS + SP) in 180 children of age 6–59 months with uncomplicated malaria in Democratic
Republic of Congo. Children were randomly allocated to receive 3 days observed treatment of AS + AQ
(n ¼ 90) or 3 days of AS + SP (n ¼ 90). Primary efﬁcacy outcomes were 28-day parasite recurrence rates,
and recrudescence rates were adjusted by genotyping to distinguish new infection and recrudescence. In
addition, we determined the prevalence of molecular markers of resistance to sulphadoxine and
pyrimethamine. Day 28 parasite recurrence rates were 16.9% (14/83; 95% CI: 9.5–26.7) in the AS + AQ
group and 34.6% (28/81; 95% CI: 24.3–46.0) in the AS + SP group (P ¼ 0.009). After PCR correction,
recrudescence rates were 6.7% (5/74; 95% CI: 2.2–15.1) for AS + AQ and 19.7% (13/66; 95% CI: 10.9–
31.3) for AS + SP (P ¼ 0.02). There was no signiﬁcant difference between the two arms in time to
parasite clearance, fever clearance and gametocyte clearance. Parasite genotyping showed high
frequencies of dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) molecular SP-
resistance markers, with 57% of the samples showing more than three mutations linked to SP resistance,
and 27% with triple-dhfr/double-dhps haplotype, conﬁrming that SP treatment failure rates are likely to
be high. AS + AQ had signiﬁcantly higher efﬁcacy than AS + SP. These results contributed to the
subsequent change to AS + AQ as ﬁrst-line regimen in the country. Efforts to properly implement the new
protocol and maintain adherence at acceptable levels should include health staff and patient sensitization.
The 6.8% recrudescence rate indicates that AS + AQ should be monitored closely until a more effective
artemisinin combination therapy regimen is needed and can be introduced.
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Introduction
Malaria remains a major health problem in the tropics, and
Plasmodium falciparum resistance to common antimalari-
als poses a formidable obstacle for malaria control.
Currently, new treatment policies are being developed and
are in the process of implementation in many countries.
However, many national health care systems in Africa lack
the resources to respond adequately to this demand
without international assistance. In areas such as eastern
Democratic Republic of Congo (DRC), which recently
experienced prolonged civil war and population displace-
ment, primary health care has deteriorated and is not
readily accessible to the whole population.
Resistance to chloroquine (CQ) has been documented in
the DRC as early as 1983 (Delacolette et al. 1983) and
reached levels of 29–80% (WHO 2005a). During
2001–2002, the DRC Ministry of Health (MOH) con-
ducted studies in seven sentinel sites in various DRC health
zones. These showed an emerging resistance to
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National de Lutte contre le Paludisme (PNLP) 2002; WHO
2005a). A multisite assessment showed 14-day sulpha-
doxine–pyrimethamine (SP) failure rates of 19.2% in the
eastern region (Kazadi et al. 2003). A survey in southeast
DRC showed an alarmingly low 49% efﬁcacy of SP at day
14 (J .M. Escriba, unpublished data, MSF-Spain in Pweto,
Katanga in 2002). Results of a recent assessment of the
prevalence of SP resistance markers in central and eastern
DRC also suggested high resistance to pyrimethamine alone
or combined with sulphadoxine (Cohuet et al. in press).
In 2001, the WHO recommended the use of artemisinin-
based combinations [artesunate + sulphadoxine–pyri-
methamine (AS + SP), artesunate + amodiaquine
(AS + AQ), artemether–lumefantrine)] as ﬁrst-line treat-
ment for uncomplicated falciparum malaria in response to
reduced effectiveness of CQ and SP monotherapy, as seen
in the DRC. In 2003, the DRC national malaria pro-
gramme changed the protocol from CQ to SP monotherapy
as an interim therapy, to be followed by an artemisinin
combination therapy (ACT) in 1–2 years. In February
2005, the MOH of DRC made its choice for a modiﬁed
national protocol, replacing SP with AS + AQ therapy.
Although no trials on the efﬁcacy of AQ or AQ + AS in the
DRC were completed prior to this study, trials in various
other parts of Africa had shown the safety and efﬁcacy of
AS + AQ (Adjuik et al. 2002) even in areas of moderate
resistance to amodiaquine.
Until the time of study (2004), ongoing conﬂict limited
research in this region and delayed efforts to identify an
appropriate alternative ACT regimen. Me ´decins sans
Frontie `res (MSF) has managed health projects in the DRC
since the 1980s and recently has played an active role in
ACT implementation and ACT efﬁcacy trials in other parts
of Africa, such as Sierra Leone, Sudan and Uganda (van
den Broek et al. 2005; Checchi et al. 2005; Piola et al.
2005). This experience was used to set up a study in a
remote area of DRC, South Kivu, in order to compare the
efﬁcacy of two ACTs eligible for the national protocol.
Methods
Study site
The DRC is Africa’s third largest country with an
estimated population of 53 million in 2002. A prolonged
civil war has led to large numbers of internally displaced
persons and degradation of infrastructure, including the
health delivery systems. Health indicators for the DRC are
among the worst in Africa (WHO 2005b). The Shabunda
Health Zone population is estimated at 588 000. The study
site was the small town of Shabunda in the South Kivu
province, mid-east DRC, very isolated and accessible only
by plane or on foot.
Malaria is highly endemic and seasonal. Malaria trans-
mission is intense and perennial throughout the DRC, with
peaks during the low (March to May) and high (September
to November) rainy season and higher levels in rural than
in urban environments. The main vectors are Anopheles
gambiae ss and Anopheles funestus (Coene 1993). The
level of malaria transmission is not homogeneous over the
country, with its large size and variations in climate and
topography. Large-scale displacement of populations
because of ongoing conﬂict has blurred the edges of these
areas, and the transmission patterns are not predictable.
Study design and patients
Following WHO guidelines for monitoring antimalarial
drug efﬁcacy (WHO 2003), we recruited patients with
uncomplicated P. falciparum malaria proved by blood ﬁlm
from the ‘Divine Maitre’ Health Centre of Shabunda.
Nurses interviewed the parents or guardians of all febrile
children who were routine users of the health centre and
those with temperature ‡ 37.5  C were referred to the
study team. All referred patients were interviewed again
and clinically examined to exclude concomitant infections.
Duplicate thick and thin ﬁlm blood smears were examined
for the presence of malaria parasites. Blood samples for
PCR genotyping analysis were collected on glass ﬁbre ﬁlter
paper. Haemoglobin (Hgb) was measured using the Lovi-
bond technique (Assistant Co., Sondheim Rhon,
Germany). Children were eligible for inclusion if they were
of age 6–59 months, had symptoms suggestive of clinical
malaria and P. falciparum parasitaemia of at least 2000
parasites per ll of blood, were able to take study drugs by
the oral route, were able to attend the clinic on stipulated
days for follow-up and if a parent or guardian provided
written informed consent for the child. Exclusion criteria
consisted of (1) presence of severe and complicated malaria
as deﬁned by WHO (WHO 2003), (2) a mixed plasmodial
infection or concomitant disease that could mask the
response to antimalarial treatment, (3) P. falciparum
parasitaemia higher than 200 000 parasites per ll of blood,
(4) or known hypersensitivity to any of the study drugs.
Children were randomly assigned to one of the two
study regimens. Randomization in blocks of 12 was
performed by computer before the study started, using a
1:1 ratio. To each inclusion number corresponded a sealed
envelope containing the treatment allocation; each envel-
ope was opened only after informed consent had been
obtained. Neither patients nor clinicians were blinded to
the treatment given. All treatments were given under direct
observation, and patients were observed for 30 min
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ﬁrst 30 min, a repeat dose was administered. If this dose
was also vomited, the child was withdrawn from the study
and referred to the general reference hospital for appro-
priate management.
Study procedures during follow-up
Parents were asked to bring their children back to the clinic
on days 1, 2, 3, 7, 14, 21 and 28 after the start of treatment
or on any other day if the child was unwell. Children were
examined by the study team and treated appropriately.
Parents or guardians were asked for any potential side
effects of the drug and the child’s tolerability to the
treatment. Children with early and late treatment failures
were given quinine 10 mg/kg/day three times a day for
7 days. Patients with any sign of severe malaria were
admitted to hospital and treated with intravenous quinine.
Children who did not attend on planned clinic days were
visited at their homes by a study tracer and were
encouraged to attend the next day.
Laboratory methods
Blood ﬁlms were taken on day 0, 2, 3, 7, 14, 21 and 28,
combining thick and thin smears on one slide. Thick ﬁlm
microscopy was used to determine parasite density and thin
ﬁlm microscopy to determine parasite species and stage.
Slides were stained with 10% pre-ﬁltered Giemsa solution
for 30 min. Both asexual parasites and gametocytes were
counted per 200–500 white blood cells (WBCs) and the
density, expressed in parasites per ll of blood, was
calculated assuming a standard of 8000 WBCs per ll. A
slide was reported negative when examination of 100 ﬁelds
of a thick smear showed no presence of asexual parasites.
Microscopists unaware of treatment allocation read all
slides. Internal quality control included a blind second
reading of a proportion of the slides by a second micros-
copist: all slides taken during day 0 and day 3, all positive
slides after day 3 and 20% of negative slides. All day 28
negative slides were reread. Discordances were resolved by
a third, experienced reader. External controls were con-
ducted by an MOH reference lab in the provincial capital.
Clinical and parasitological outcomes were graded
according to WHO 2003 guidelines (WHO 2003). Clinical
failure was deﬁned as parasites recorded in combination
with clinical symptoms at any follow-up visit after day 2 of
treatment; parasitological failure was deﬁned as parasites
recorded at the last day of follow-up, day 28, without
presence of symptoms.
On day 0 (pre-treatment), and the day of failure
endpoint if applicable, a dry blood spot was collected on
glass ﬁbre ﬁlter paper (Item No. 1205-401; Perkin-Elmer)
for genotyping to distinguish recrudescence from reinfec-
tion in cases of treatment failure, estimation of the
multiplicity of infection (MoI) and determination of the
prevalence of molecular markers associated with SP
resistance. Differentiation between recrudescence and new
infections was based on protocols developed by Snounou
et al.(1999).Inbrief,sixseparatenestedPCRreactionswere
performed with oligonucleotide primer pairs speciﬁc for the
three allelic families of msp-1 (MAD20, K1 and R033), and
two allelic families of msp-2 (FC27 and IC). Size poly-
morphism was analysed by electrophoresis on agarose gel
and visualized by UV transillumination. MoI was obtained
bymultiplyingthenumberofallelesineachmsp1andmsp2.
A conservative estimate was used, represented by the
minimum number of genotypes (i.e. the highest number of
genotypes within any one of the two markers).
Molecular determination of resistance to sulphadoxine
and pyrimethamine was determined by a PCR approach
using sequence-speciﬁc probes for the detection of known
single-nucleotidepolymorphismsconferringresistancetoSP
(Pearce et al. 2003). Parasite DNA from pre-treatment
blood samples were ampliﬁed and screened using the
PCR-SSOP (polymerase chain reaction using sequence-
speciﬁc olignucleotide probes) technique for mutations
associated with SP resistance. The samples were genotyped
for mutations in codons 50, 51, 59 and 108 in dihydrofolate
reductase(dhfr),conferringresistancetopyrimethamineand
in codons 436, 437 and 540 of dihydropteroate synthase
(dhps), known to furtherenhance resistance. PCR-ampliﬁed
coding regions of dhfr and dhps genes were ﬁxed on
membrane and probed with sequence-speciﬁc oligonucleo-
tide probes designed to detect each of the single-base-pair
substitutions at the codons given in Table 1.
Sample size
The intent was to estimate the efﬁcacy of the two
combination treatments, accepting a risk of type I error of
5%, with a precision of 10%. Therefore, a sample size of at
least 73 patients in each arm was planned with estimated
80% efﬁcacy (Epi-info 6.0; Centre for Disease Control,
Atlanta, GA, USA). Adding 15% to account for defaulters,
84 patients per arm had to be recruited, thus totalling at
least 168.
Data analysis
Data was double-entered into Excel (Microsoft XP) and
transferred to STATA (version 8.0; Stata Corporation,
College Station, TX, USA) for further analyses. Statistical
tests used were chi-square tests to compare categorical
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n ¼ 5. Continuous data were tested for normality (test for
skewness, Shapira–Wilk test for normality). Normally
distributed data were analysed with t-tests and anova.
Primary efﬁcacy outcomes were 28-day true failure rates,
adjusted by genotyping to distinguish new infection and
recrudescence. Secondary endpoints included gametocyte
clearance rates, changes in Hgb concentration and levels of
molecular SP resistance.
Ethics review
The ethics committee of the DRC National Malaria
Programme and the external Ethics Review Board used by
MSF reviewed and approved the study protocol. The study
was discussed with and approved by community leaders
before its start. Parents or guardians of children were asked
for informed written consent before inclusion of their child
in the study.
Results
Between 1 April and 13 May 2004, 435 children were
screened for inclusion. Of these, 180 were recruited into
the study and 256 children were excluded: 137 slide
negative, 33 with parasitaemia <2000/ll, 14 with parasit-
aemia >200 000/ll, 44 with serious concomitant infec-
tions, 22 with presence of non-falciparum infection and 6
living too far from the study site. Microscopy results from
251 screened positive patients showed that 91.2% (229)
were pure P. falciparum infections, 6.4% (16) P. falcipa-
rum + Plasmodium malariae, 0.4% (1) P. falcipa-
rum + Plasmodium ovale, 1.6% (4) P. malariae and 0.4%
(1) P. ovale.
The 180 children who met entry criteria were randomly
assigned to one of the two drug combinations. Baseline
characteristics (Table 1) were similar across treatment
groups. After inclusion, ﬁve were withdrawn (one because
of incorrect inclusion, two for intake of non-study
antimalarials and two for vomiting the treatment dose
twice). Eleven children were lost to follow-up (1 because of
family movement, 10 by an inability to complete a day 28
visit after evacuation of the study team because of political
insecurity). There was no signiﬁcant difference between
cases lost to follow-up or withdrawn in the AS + SP (9/90)
and AS + AQ group (7/90; P ¼ 0.21).
The results of external quality control of 73 slides
revealed three disagreements in the presence of P. falcipa-
rum parasites, which were all at a density of less than 50
parasites per ll. Additionally, three slides had different
ﬁndings for P. falciparum gametocytes, and in one slide the
reference laboratory reported the presence of P. ovale
parasites. None of the discrepancies changed the outcome
of treatment.
Primary outcomes
Parasitological and clinical outcomes were available from
164 children at day 28 (Table 2). By day 14, one child in
the AS + SP group experienced late clinical failure and was
re-treated. Within the 28 days of follow-up, 42 children
were re-treated: 16.9% (14/83) in the AS + AQ group and
34.6% (28/81) in the AS + SP group. Table 3 shows the
classiﬁcation of treatment outcome at day 28 before
correction by PCR analysis. Two samples were removed
from the AS + SP group because of indeterminate PCR
results. PCR genotyping identiﬁed 9 of 14 recurrent
parasitemias in the AS + AQ group and 13 of 26 in the
AS + SP group as new infections, and these were removed
from ﬁnal analysis as per protocol (WHO 2003). After
correction by PCR, ﬁnal analysis showed a 6.8% recru-
descent rate in the AS + AQ group and a 19.7% recru-
descent rate in the AS + SP group (Table 3, bottom row).
Secondary outcomes
Fever clearance was complete within 2–3 days for both
therapies and showed no signiﬁcant difference between the
Table 1 Mutant and wild-type amino acids
at dhfr and dhps loci dhfr – codons dhps – codons
50* 51 59 108 436* 437 540
Mutation R, CGT I, ATT R, CGT N, AAC
T, ACC
F, TTT
A, GCT
C, TGT
G, GGT E, GAA
Wild-type C, TGT N, AAT AAC C, TGT S, AGC S, TCT A, GCT K, AAA
Letter codes show amino acids and codons; those that result from mutations are shown in
bold.
*The numbers represent amino acid positions in dhfr and dhps where mutations occur.
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arms with all children parasite-free by day 3. The two
treatment groups did not show a signiﬁcant difference in
gametocyte clearance rates. The proportion of cases with
gametocytes in the blood increased during the ﬁrst 2 days
of treatment. Thirteen percentage had gametocytes at the
day of inclusion and a further 23% of cases without
gametocytes at enrolment developed detectable gameto-
cytemia. This percentage dropped in both treatment groups
after treatment, with more than 95% of cases free from
gametocytes by day 21. The percentage of patients with
mild (Hgb 8–10.9 g/dl) and moderate anaemia (Hgb
5–7.9 g/dl) dropped from 67% (116/173) and 14%
(24/173) at the time of recruitment to 48% (71/148) and
3% (5/148) by day 28, respectively. There were no adverse
side effects reported by parents, and drug regimens were
well tolerated.
Genotyping of the pre-failure samples (n ¼ 42) showed
that patients were infected by multiple P. falciparum
strains at the time of screening, with an MoI of 3.0 (126
strains in 42 infections).
Molecular markers of sulphadoxine–pyrimethamine
resistance
PCR-SSOP identiﬁed the sensitive and single-, double- or
triple-mutant dhfr and dhps haplotypes commonly recor-
ded in African populations. Of 217 samples screened for
dhps, 177 single and majority genotype infections could be
deduced for this locus; excluded from analysis were 11
PCR-negative samples and 29 mixed infections. Of 182
samples screened for dhfr, 158 could be analysed; excluded
from analysis were 7 PCR-negative samples and 17 mixed
infections.
A high prevalence of key mutations for SP resistance at
dhfr and dhps were found (Table 4). At dhps, four different
alleles were identiﬁed: 30% of parasites had the sensitive
haplotype, 24% the single-mutant S436A, 1% the single-
mutant A437G and 45% the double-mutant A437G
K540E allelic haplotype. Five dhfr alleles were identiﬁed:
8% of parasites had the sensitive dhfr allele, 3% had a
single S108N mutation, 39% had a double-mutant N51I,
S108N allele, 4% a C59R, S108N double-mutant allele
Table 2 Baseline characteristics included children, by treatment group
AS + AQ (n ¼ 90) AS + SP (n ¼ 90) Total (n ¼ 180) P-value
Female, n (%) 45 (50) 36 (40) 81 (45%) 0.20
Age (months), mean ± SD 23.7 ± 12.9 23.7 ± 14.5 23.7 ± 13.6 0.71
Haemoglobin (Hgb, g/dl), mean ± SD 9.8 ± 1.5 9.7 ± 1.7 9.8 ± 1.6 0.95
Moderate anaemia (Hgb 5 to <8 g/dl), n (%) 9 (10) 15 (17) 24 (14%) 0.27
Mild anaemia (Hgb 8 to <11 g/dl), n (%) 64 (71) 56 (63) 120 (67%) 0.27
Temperature (  C), Mean ± SD 38.8 ± 0.8 38.7 ± 0.9 38.8 ± 0.9 0.59
Parasite density (per ll blood),
geometric mean (range)
27 392 (2200–180 560) 21 360 (2040–179 200) 24 492 (2040–180 560) 0.20
Gametocytaemic, n (%) 11 (12.2) 12 (13.5) 23 (12.8) 0.80
Gametocytaemia (per ll blood), mean (range) 255 (40–1920) 87 (40–200) 167(40–1920)
Table 3 Efﬁcacy at day 28 days
Endpoint
AS + AQ AS + SP
Chi-square % n 95% CI % n 95% CI
ACPR 83.1 69 73.3–90.5 65.4 53 54.0–75.6 P ¼ 0.009
ETF 0 0 0–4.3 0 0 0–4.5
LCF 10.8 9 5.1–19.5 17.3 14 9.8–27.3 P ¼ 0.24
LPF 6.0 5 2.0–13.5 17.3 14 9.8–27.3 P ¼ 0.02
Failure rate
Before PCR conﬁrmation 16.9 14/83 9.5–26.7 34.6 28/81 24.3–46.0 P ¼ 0.009
After PCR conﬁrmation 6.8 5/74 2.2–15.1 19.7 13/66 10.9–31.3 P ¼ 0.02
ACPR, adequate clinical and parasitological response; ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological
failure.
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(numbers indicate positions at dhfr locus and letters the
amino acid at this position before and after mutation).
Analysis of the combined dhfr and dhps genotypes showed
that only 3% of all parasites were sensitive at both loci,
while the majority, 78%, had three or more mutations
linked to SP resistance. The genotype that is most closely
associated with SP treatment failure in vivo is the triple-
mutant dhfr N51I, C59R, S108N in combination with
double-mutant dhps A437G K540E. This genotype was
present in 27% of parasites.
Discussion
Here we report results from one of the ﬁrst ACT drug
efﬁcacy trials in eastern DRC. We found that the combi-
nation AS + AQ performed better than AS + SP in the
28 days after observed treatment, with AS + SP failing in
20% of patients after 28 days. Both treatment groups had
similarly positive secondary treatment outcomes, including
rapid fever and parasite clearance, effect on gametocytae-
mia and recovery of Hgb values. Regarding implementa-
tion of the new national treatment protocol, AS + AQ is
conﬁrmed to be the more effective option in this region.
Molecular genetic analysis of day 0 samples showed high
prevalence of SP-resistant parasites among the patient
cohort. Resistance mutations were common in both dhfr
and dhps genes and 27% of the parasites were shown to
have a combination of both the triple-mutant dhfr and the
double-mutant dhps, which has been demonstrated to be
predictive of treatment failure (Kublin et al. 2002;
Kyabayinze et al. 2003; Omar et al. 2005). The triple-
mutant dhfr alone is refractory to SP (Plowe et al. 1998)
and this was found in almost half of parasites. Cohuet
et al. in press recently reported similar molecular results
(P. falciparum from Equator, Oriental and Katanga prov-
inces in the DRC), highlighting the need to discontinue the
use of SP, whether in monotherapy or in combinations in
this region. These study results add to the growing body of
knowledge that AS + SP is disappointingly ineffective
where the level of SP resistance is high (WHO 2005b).
Amodiaquine has a metabolism, structure and mode of
action very different from SP and problems of amodiaquine
resistance are less widespread regionally (East African
Network for Monitoring Antimalarial Treatment
(EANMAT) 2004).
Hence, the combination AS + AQ is not only more
effective than AS + SP at present but also may remain
effective for an extended period of time. Combinations
with AS have proved very efﬁcacious and could, in the right
circumstances, protect drugs from the progressive devel-
opment of resistance, as has been shown with implemen-
tation of ACT elsewhere (Nosten & Brasseur 2002).
AS + AQ has now been adopted as ﬁrst-line antimalarial
treatment in 15 countries in Africa (WHO 2006). The
combination AS + AQ was evaluated positively in a
number of recent studies in Africa, showing 28-day
corrected efﬁcacies >90% (range 90.3–100%) in most
locations (Barennes et al. 2004; Rwagacondo et al. 2004;
Staedke et al. 2004; van den Broek et al. 2005; Guthmann
et al. 2005; Hamour et al. 2005; Martensson et al. 2005;
Yeka et al. 2005; S. Cohuet, M. Bonnet, Epicentre/MSF
unpublished data). In some locations, however, the efﬁcacy
of this combination was below 90% (range 73.0–86.7;
Rwagacondo et al. 2004; Grandesso et al. in press).
The gametocidal effect is important for ACT capacity to
reduce malaria transmission (Price et al. 1996). In our
study, gametocytes developed later in a quarter of the
patients. This occurred mainly during the ﬁrst 2 days, after
one or two doses of the AS course had been taken; this
pattern was similar in both ACT groups. Artemisinins act
through suppressing the development of new gametocytes
(Pukrittayakamee et al. 2004) and might therefore not
affect gametocytes that are already (nearly) formed. In
patients treated with non-artemisinin antimalarial drugs or
untreated (asymptomatic) persons, gametocytes develop
for a longer period after asexual parasite stages are cleared
(Bousema et al. 2004). Drug-resistant strains also show
higher gametocytaemia than sensitive strains (Sowumni &
Table 4 Haplotype frequencies in dhfr and dhps loci in P. falci-
parum infections
Genotype* Count %
dhfr (n ¼ 158)
Sensitive CNCS 12 7.6
Single-mutant 108 CNCN 5 3.2
Double-mutant 51, 108 CICN 62 39.2
Double-mutant 59, 108 CNRN 6 3.8
Triple-mutant 51, 59, 108 CIRN 73 46.2
dhps (n ¼ 177)
Sensitive SAK 53 30.0
Single-mutant 436A AAK 43 24.3
Single-mutant 437 SGK 1 0.6
Double-mutant 437, 540 SGE 80 45.2
dhfr + dhps (n ¼ 0 133)
Sensitive 4 3.0
Single 3 2.3
Double 22 16.7
Triple 28 21.1
Quadruple 40 30.1
Quintuple – highly resistant 36 27.1
*The three-letter codes for dhps show amino acids at positions
436, 437 and 540. Four-letter codes at dhfr show amino acids at
positions 50, 51, 59 and 108. Amino acids that result from
mutations are shown in bold.
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important secondary treatment outcome to incorporate in
monitoring ACT efﬁcacy, although it can only be regarded
within the local and seasonal context of malaria trans-
mission.
As discussed by Mutabingwa et al. (2005), there is a
concern that efﬁcacy data are not a realistic measure of the
effectiveness of a drug in operational practice. While this
can be true, effective sensitization efforts will improve drug
adherence, especially if in collaboration with an easily
dispensed and consumed drug formula, as seen when using
WHO packaging of Coartem (Fogg et al. 2004; Muta-
bingwa et al. 2005). To this end, there must be an ongoing
push for the introduction of an AS + AQ co-formulation in
blister pack, which is foreseen to become available in 2006.
Importantly, there is also a need to establish a better system
of diagnostics, in order to prevent unnecessary use of
ACTs, which masks its effectiveness to the users. It will
take a major shift in mindset and practice to make the
African health care providers see that fever does not equal
malaria (Malenga et al. 2005).
In 1990, the WHO withdrew amodiaquine for the
treatment of malaria after reports of rare but severe toxic
effects associated with its use as prophylaxis. Subsequent to
systematic review of trials (Olliaro et al. 1996) showing the
safety of amodiaquine when given as 3-day treatment, the
WHO modiﬁed its recommendations to reinstate amo-
diaquine for the treatment of falciparum malaria. In the
DRC, this information has not yet penetrated to all remote
rural health centres and, therefore, health staff, community
health care volunteers and patients will need to be
sensitized to these recommendations in efforts to ensure
AS + AQ is effectively accepted and implemented.
In countries such as the DRC, with a per capita gross
domestic product of US$352 and a total health expenditure
per capita of US$12 (WHO 2005b), local capacity to
provide ACT is very limited. The cost of treatment has to
be considered, as this is a limiting factor to the success of
implementation (Whitty et al. 2004). Price for patients has
to be kept as low as possible and preferably free. In the
DRC, this will require the ongoing assistance of external
donors. The Global Fund as well as some other donors has
shown a willingness to make available extra funds for this
treatment at a regional or national level (Global Fund
2004; WHO 2006).
This article highlights the difﬁcult predicament many
African countries continue to face today. With the high
cost of effective ACT, many African countries are forced to
rely on ineffective antimalarials. Although AS + AQ was
shown to be highly effective in our study in the DRC, a
failure rate of 6.8% is worthy of concern. Our results
support the change in national protocol to AS + AQ as
ﬁrst-line treatment of uncomplicated malaria, with the
proviso that the monitoring of both efﬁcacy and effective-
ness must continue.
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Arte ´sunate + Amiodaquine et Arte ´sunate + Sulfadoxine–Pyrime ´thamine dans le traitement de l’acce `s palustre simple en Re ´publique De ´mocratique du
Congo : e ´tude clinique avec de ´termination des haplotypes de re ´sistance de la sulfadoxine et de la pyrime ´thamine
Nous avons mene ´ une e ´tude sur l’Arte ´sunate + Amiodaquine (AS + AQ) et Arte ´sunate + Sulfadoxine–Pyrime ´thamine (AS + SP) chez 180 enfants a ˆge ´s
de 6 a ` 59 mois pre ´sentant un acce `s palustre simple en Republique Democratique du Congo (RDC). Les enfants recevaient de fac ¸on randomise ´e 3 jours de
traitement supervise ´ d’AS + AQ (n ¼ 90) ou 3 jours d’AS + SP (n ¼ 90). Les crite `res de jugement principaux e ´taient les taux de re ´infection au 28e ´me
jours et les taux de rechutes ajuste ´s selon le ge ´notype permettant de diffe ´rencier une nouvelle infection d’une rechute. De plus, nous avons de ´termine ´ la
pre ´valence des marqueurs mole ´culaires de re ´sistance a ` la sulfadoxine et a ` la pyrime ´thamine. Les taux de reinfection au 28e ´me jours e ´taient de 16.9%
(14/83; IC 95%: [9.5; 26.7]) dans le groupe AS + AQ et 34.6% (28/81; IC 95% [24.3; 46.0]) dans le groupe AS + SP (P ¼ 0,009). Apres correction par
PCR, les taux de rechute e ´taient de 6.7% (5/74; IC 95% [2.2; 15.1]) pour l’AS + AQ et 19.7% (13/66; IC 95% [10.9)31.3]) pour l’AS + SP (P ¼ 0.02).
Il n’y avait pas de diffe ´rence statistiquement signiﬁcative entre les deux bras en terme de delai de ne ´gativation de la parasite ´mie, de disparition de la
ﬁe `vre et de disparition des game ´tocytes. Le ge ´notypage parasitaire montrait une fre ´quence e ´leve ´e des marqueurs de re ´sistance mole ´culaire a ` la SP pour la
dhfr et la dhps avec 57% des e ´chantillons montrant plus de 3 mutations lie ´es a la re ´sistance a ` la SP et 27% avec l’haplotype triple-dhfr/double-dhps,
conﬁrmant que le taux d’e ´chec du traitement par SP est probablement e ´leve ´. AS + AQ avait de fac ¸on signiﬁcative une efﬁcacite ´ supe ´rieure en
comparaison a ` AS + SP. Ces re ´sultats ont favorise ´ un changement de traitement pour l’association AS + AQ en premie `re ligne de traitement dans le
pays. Les efforts pour mettre en place correctement le nouveau protocole et maintenir l’adhe ´rence a ` des niveaux acceptables devraient inclure la
sensibilisation aussi bien du personnel de sante ´ que du patient. Le taux de rechute de 6,8% indique que le traitement par AS + AQ devrait e ˆtre surveille ´
de fac ¸on rapproche ´e jusqu’a ` ce qu’une nouvelle Association Combine d’Artemisine (ACT) plus efﬁcace soit disponible et puisse e ˆtre utilise ´e.
mots clefs paludisme, efﬁcacite ´, sulfadoxine–pyrime ´thamine, amiodaquine, arte ´sunate, haplotype de re ´sistance, Re ´publique De ´mocratique du Congo
Artesunato + Amodiaquina y Artesunato + Sulfadoxina–Pirimetamina para el tratamiento de la malaria no complicada en la Repu ´blica Democra ´tica
del Congo: una prueba clı ´nica con determinacio ´n de los haplotipos resistentes a la sulfadoxina y pirimetamina
Llevamos adelante un ensayo de Artesunato + Amodiaquina (AS + AQ) y Artesunato + Sulfadoxina-Pirimetamina (AS + SP) entre 180 nin ˜os de 6 a 59
meses de edad con malaria no complicada en la Repu ´blica Democra ´tica del Congo (RDC). Los nin ˜os fueron asignados de forma aleatoria para recibir un
tratamiento controlado de 3 dı ´as de AS + AQ (n ¼ 90) o 3 dı ´as de AS + SP (n ¼ 90). Los resultados de eﬁcacia primaria eran de tasas de recurrencia de
para ´sitos de 28 dı ´as, y las tasas de recrudescencia fueron ajustadas por genotipiﬁcacio ´n para distinguir nuevas infecciones de las recrudescentes. Sumado
a ello, determinamos la prevalencia de marcadores moleculares de resistencia a la sulfadoxina y la pirimetamina. Las tasas de recurrencia de para ´sitos al
dı ´a 28 eran de 16.9% (14/83; 95% CI: 9.5–26.7) en el grupo AS + AQ y 34.6% (28/81; 95% CI: 24.3–46.0) en el grupo AS + SP (P ¼ 0.009). Despue ´s
de la correccio ´n PCR, las tasas de recrudescencia eran 6.7% (5/74: 95% CI: 2.2–15.1) para AS + AQ y 19.7% (13/66; 95% CI: 10.9–31.3) para AS + SP
(P ¼ 0.02). No hubo diferencia signiﬁcativa entre los dos grupos al momento de la eliminacio ´n de los para ´sitos, la eliminacio ´n de la ﬁebre y la
eliminacio ´n de los gametocitos. La genotipiﬁcacio ´n del para ´sito mostro ´ altas frecuencias de marcadores moleculares de resistencia SP dhfr y dhps, con
un 57% de las muestras mostrando ma ´s de 3 mutaciones ligadas a resistencia SP, y 27% con haplotipo triple-dhfr/double-dhps, conﬁrmando que las
tasas de fracaso del tratamiento SP sera ´n probablemente altas. AS + AQ tiene signiﬁcantemente mayor eﬁcacia que AS + SP. Estos resultados con-
tribuyeron al subsiguiente cambio a AS + AQ como primera lı ´nea de tratamiento en el paı ´s. Los esfuerzos para implementar apropiadamente los nuevos
protocolos y para mantener la adherencia en niveles aceptables deberı ´a incluir la sensibilizacio ´n de los pacientes y del personal sanitario. La tasa de
recrudescencia del 6.8% indica que el AS + AQ deberı ´a ser monitoreado estrechamente hasta el momento en el que sea necesaria una Terapia de
Combinacio ´n de Artemisinina (TCA), y esta terapia pueda ser introducida.
palabras clave malaria, eﬁcacia, sulfadoxina–pirimetamina, amodiaquina, artesunato, haplotipo resistente, Repu ´blica Democra ´tica del Congo
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